Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs ON Holding AG (ONON) Price & Performance

Inovio Pharmaceuticals IncTrade
ON Holding AGTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs ON Holding AG — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while ON Holding AG trades at $31.1 (market cap $10.33B). The key difference: ON Holding AG is far larger — about 131.5× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

INOONON
Market Cap
$78.55M$10.33B
Sector
HealthTechnology
52-Week High
$2.87$50.63
52-Week Low
$0.66$30.91
Enterprise Value
$49.56M$9.47B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

ON Holding AG

ONON stock plunged 19.93% to $31.05 after Q2 2026 results, driven by a revenue miss and lowered full-year growth guidance. Despite beating EPS estimates in recent quarters, the company faces wholesale channel softness and cautious consumer spending. Technical indicators are bearish, with the price near key support at $30, while fundamentals show strong profitability margins and positive cash flow trends. Analyst sentiment remains largely bullish with a $52.86 consensus target, but near-term volatility persists.

The outlook is mixed: long-term growth potential exists via direct-to-consumer strength and margin expansion, but investors face risks from guidance uncertainty and competitive pressures. The sharp sell-off may present a buying opportunity for patient investors, though volatility could continue until wholesale trends stabilize.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About ON Holding AG

ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.

Read more on ONON